Evaluation of the Myocilin Mutation Gln368Stop Demonstrates Reduced Penetrance for Glaucoma in European Populations by Nag, Abhishek et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ophtha.2016.11.018
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Nag, A., Lu, H., Arno, M., Iglesias, A. I., Bonnemaijer, P., Broer, L., ... Hammond, C. J. (2016). Evaluation of the
Myocilin Mutation Gln368Stop Demonstrates Reduced Penetrance for Glaucoma in European Populations.
Ophthalmology. https://doi.org/10.1016/j.ophtha.2016.11.018
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Evaluation of the myocilin mutation Gln368Stop (rs74315329) 1 
demonstrates reduced penetrance in European populations 2 
 3 
Abhishek Nag
1
, Han Lu
2
, Matthew Arno
2
, Adriana I. Iglesias
3,4
, Pieter 4 
Bonnemaijer
3,4
, Linda Broer
5
, Andre G. Uitterlinden
3,5,6
, Caroline C.W. 5 
Klaver
4
, Cornelia van Duijn
3
, Pirro G. Hysi
1,7
, Christopher J. Hammond
1,7
 6 
 7 
 8 
1
Department of Twin Research and Genetic Epidemiology, King's College London, St. Thomas' Hospital, 9 
London, UK 10 
2King’s Genomics Facilities, King’s College London, London, UK 11 
3
Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 12 
4
Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands 13 
5
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands 14 
6
Netherlands Consortium for Healthy Ageing, Netherlands Genomic Initiative, the Hague, the Netherlands 15 
7
Department of Ophthalmology, King’s College London, London, UK 16 
 17 
 18 
 19 
 20 
Corresponding author 21 
Prof. Christopher J. Hammond 22 
Department of Twin Research and Genetic Epidemiology, 23 
King’s College London, 24 
St. Thomas’ Hospital, 25 
London 26 
United Kingdom 27 
Email: chris.hammond@kcl.ac.uk 28 
Financial Support 29 
The study was part-funded by Fight for Sight (A.N., P.G.H) and the 30 
International Glaucoma Association (C.J.H.). TwinsUK is supported by the 31 
Wellcome Trust (grant WT081878MA) and the European Commission's 32 
Seventh Framework Programme (FP7/2007–2013). SNP Genotyping was 33 
performed by National Eye Institute via NIH/CIDR (grant R01EY018246-34 
01-1, PI Young TL) and the Wellcome Trust Sanger Institute. The study also 35 
receives support from the National Institute for Health Research (NIHR)-36 
funded BioResource, Clinical Research Facility and Biomedical Research 37 
Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership 38 
with King's College London. 39 
The sponsor or funding organization had no role in the design or the conduct 40 
of this research. 41 
 42 
Conflict of Interest 43 
No conflicting relationship exists for any author  44 
 45 
Running Title 46 
Gln368Stop myocilin mutation and glaucoma 47 
 48 
Abbreviations and Acronyms 49 
MYOC (myocilin), POAG (primary open-angle glaucoma), OPTN 50 
(optineurin), GWAS (genome-wide association study), JOAG (juvenile 51 
open-angle glaucoma), OR (odds ratio), IOP (intraocular pressure), ORA 52 
(Ocular Response Analyser), RS (Rotterdam Study), HRC (Haplotype 53 
Reference Consortium), GVFL (glaucomatous visual field loss), MAF 54 
(minor allele frequency), CI (confidence intervals), OMIM (Online 55 
Mendelian Inheritance in Man)  56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
 70 
Abstract 71 
OBJECTIVE: Sequence variations in the myocilin (MYOC) gene account 72 
for ~2–4% of the glaucoma cases. One particular MYOC mutation, 73 
Gln368Stop (dbSNP accession number: rs74315329), is the most common 74 
genetic mutation causing glaucoma, by raising the intraocular pressure. The 75 
objective of this study was to evaluate the effect of this MYOC mutation on 76 
intraocular pressure using data from large-scale European population panels 77 
(directly sequenced and imputation-based). 78 
DESIGN: Cross-sectional, cohort study 79 
PARTICIPANTS: For this study (combined sample size of over 17,000), 80 
the discovery and the replication phases were conducted in population-based 81 
cohorts, the TwinsUK and the Rotterdam Study, respectively. 82 
METHODS: Carriers of the risk allele for rs74315329 were identified using 83 
whole-genome sequencing and imputation data (based on 1000 Genomes 84 
and Haplotype Reference Consortium panels). The effect of this variant was 85 
evaluated using intraocular pressure measurements and data on visual field 86 
testing / a diagnosis of glaucoma (if available). 87 
MAIN OUTCOME MEASURES: The penetrance of the variant 88 
rs74315329 was estimated from the percentage of the carriers of the risk 89 
allele of the variant that had high intraocular pressure (ocular hypertension) 90 
and / or glaucoma. 91 
RESULTS: In our study, the observed penetrance of the variant rs74315329 92 
in relation to raised intraocular pressure was 12.5% and 19.4% in the 93 
TwinsUK and the Rotterdam Study respectively, suggesting a much lower 94 
penetrance for high intraocular pressure (and hence, glaucoma) in 95 
comparison to that reported previously. 96 
CONCLUSIONS: The significance of this finding is that higher numbers of 97 
healthy individuals in the population are expected to be carriers of this 98 
mutation, which in turn reduces the utility of identifying carriers of this 99 
mutation as a screening tool for glaucoma. 100 
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 108 
Introduction 109 
Glaucoma is the leading cause of irreversible blindness in the world
1
. 110 
Primary open-angle glaucoma (POAG) is the commonest subtype of 111 
glaucoma occurring in Caucasian populations, accounting for about 50% of 112 
all the glaucoma cases. 113 
Several studies have reported positive family history as a risk factor for 114 
glaucoma
2–4
, thus suggesting a role of genetic factors in the development of 115 
glaucoma. 116 
Previously, linkage studies have implicated several genetic loci in the 117 
Mendelian forms of glaucoma that segregated in families (www.omim.org), 118 
with the causal gene identified at three of these loci – myocilin (MYOC) at 119 
the GLC1A locus
5
, optineurin (OPTN) at the GLC1E locus
6
 and TBK1 at the 120 
GLC1P locus
7
. More recently, the advent of genome-wide association 121 
studies (GWAS) has led to the identification of many genetic loci in 122 
association with POAG
8–10
 and its intermediate phenotypes
11–15
.  123 
MYOC, the causal gene at the GLC1A locus (OMIM 601652), was identified 124 
in pedigrees with juvenile open-angle glaucoma (JOAG), a term used to 125 
refer to POAG with an earlier age of onset and an autosomal dominant mode 126 
of inheritance
16
. Sheffield et al. (1993)
17
 first reported the GLC1A linkage 127 
locus (mapping to chromosome 1q21-q31) in a family with 22 members 128 
affected with JOAG. Subsequently, Stone et al. (1997)
5
, using a combination 129 
of fine-mapping and candidate gene approach at the 1q21-q31 locus, 130 
identified missense mutations within the MYOC gene [also known as 131 
trabecular meshwork-induced glucocorticoid response protein (TIGR) gene] 132 
that segregated with the disease. Since then, several other investigators have 133 
reported MYOC mutations segregating within families of JOAG as well as 134 
adult-onset POAG
18–21
. Moreover, analysis of MYOC mutations in sporadic 135 
cases of POAG from various ancestries (Caucasian, Asian and African-136 
American) has demonstrated that a range of probable disease-causing MYOC 137 
mutations account for ~2–4% cases22,23. 138 
To date over 100 MYOC gene mutations (~85% of which are missense) have 139 
been reported in association with JOAG and POAG 140 
(http://www.myocilin.com/variants.php, last accessed 25 March 2016). Of 141 
these, Gln368Stop (dbSNP accession number: rs74315329) is the 142 
commonest glaucoma-causing MYOC mutation (accounting for >40% of the 143 
POAG cases due to MYOC mutations) in the population
5,22,23
. The higher 144 
frequency of Gln368Stop among all the known MYOC mutations, coupled 145 
with the fact that it has been reported in majority of the populations 146 
investigated so far, suggested that there might be a possible founder effect 147 
for this mutation
23
. Subsequently, studies have demonstrated that the same 148 
disease haplotype for the Gln368Stop mutation was present in 15 unrelated 149 
affected Caucasian families settled in Australia
24
 and a large affected 150 
French-Canadian family
25
, supporting a common ancestral origin for this 151 
mutation. 152 
So far, the studies that have evaluated the Gln368Stop MYOC mutation in 153 
sporadic POAG cases, have demonstrated a high odds of developing the 154 
disease with this mutation – Fingert et al. (1999)23 found that 27/1,693 155 
POAG cases carried the mutation compared to 1/793 controls (OR = 12.84). 156 
More recently, Gharahkhani et al. (2015)
26
 used an imputation-based method 157 
with the 1000 Genomes reference panel in advanced POAG cases from the 158 
ANZRAG study, and further affirmed the high effect of the Gln368Stop 159 
mutation (OR = 15.53). 160 
The Gln368Stop MYOC mutation appears to increase POAG risk by raising 161 
the intraocular pressure (IOP): sporadic as well as familial POAG cases 162 
harbouring the Gln368Stop mutation have a higher mean IOP compared to 163 
the general population, with the mean IOP for the mutation carriers ranging 164 
between 27.7 and 30 mm Hg
20,22,27–29
. 165 
The recent availability of large-scale population-based sequencing data has 166 
made it possible to evaluate the effect of Gln368Stop on POAG risk in the 167 
population at large. Here we aim to test the effect of Gln368Stop (hereafter 168 
also referred to as rs74315329) on IOP, and by extension on POAG, in 169 
European population panels using directly sequenced and imputation-based 170 
data. 171 
 172 
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Materials and Methods 190 
The primary study was conducted in the TwinsUK cohort, a population-191 
based study of healthy twin volunteers
30
. Volunteering twin siblings were 192 
unaware of the eye studies interests at the time of enrolment and gave fully 193 
informed consent under a protocol reviewed by the St. Thomas’ Hospital 194 
Local Research Ethics Committee. 195 
As a part of the UK10K project
31
, 1,854 unrelated subjects from the 196 
TwinsUK had their whole genome sequenced at a low coverage (average 197 
depth of coverage was 6x) at the Wellcome Trust Sanger Institute’s core 198 
sequencing facility with Illumina’s GAII sequencing machines. In addition, 199 
another subset of 1,190 TwinsUK subjects (which included some twin pairs) 200 
was sequenced at a much higher average depth of coverage (30x-40x). 201 
Discrete genotype calls were available for all the variable sites that were 202 
identified in the sequencing dataset, which was used to identify the 203 
TwinsUK subjects that were carriers of the allele A (hereafter referred to as 204 
the ‘risk allele’) for the variant rs74315329 in the MYOC gene. 205 
An additional subset of 3,048 TwinsUK subjects (which included some twin 206 
pairs), that was not sequenced but for which Chip genotype data were 207 
available (genotyped using two different Illumina genotyping platforms: 208 
317K Duo and HumanHap610K-Quad arrays), imputed genotypes based on 209 
the 1000 Genomes Phase 3 reference panel 210 
(http://csg.sph.umich.edu//abecasis/MACH/download/1000G.Phase3.v5.htm211 
l) were used to identify additional carriers of the risk allele for rs74315329. 212 
Phasing of the genotypes was done using the software MaCH 213 
(http://csg.sph.umich.edu//abecasis/MACH/tour/imputation.html) and 214 
genotype imputation for markers in the 1000 Genomes reference panel was 215 
done using the software Minimac 216 
(http://genome.sph.umich.edu/wiki/Minimac). Imputed data contains the 217 
probabilities of the possible genotypes at each marker. An arbitrary 218 
threshold of 80% for the probability of a heterozygous genotype was used to 219 
identify carriers of the risk allele for rs74315329. 220 
In the TwinsUK cohort, IOP was measured using the Ocular Response 221 
Analyser (ORA), a non-contact air-puff tonometer. The mean IOP of the two 222 
eyes was used for the analysis. Throughout this study, an IOP reading 223 
greater than 21 mm Hg will be considered as ‘high IOP’ i.e. ocular 224 
hypertension. For the individuals that were identified as carriers of the risk 225 
allele for rs74315329, the most recent IOP readings, visual field testing 226 
information and POAG status were obtained through follow-up with their 227 
local optician (which was on an average five years after their initial 228 
recruitment). In all the cases, follow-up IOP at the local optician was 229 
measured using a non-contact tonometer. These individuals were also 230 
enquired regarding any history of taking IOP-lowering medication and 231 
POAG diagnosis / surgery. 232 
For the TwinsUK individuals that were carriers of the risk allele for 233 
rs74315329 (identified using the whole-genome sequencing and the 1000 234 
Genomes imputation datasets, as described above), validation of the 235 
genotype for this variant was performed using Sanger sequencing. Further 236 
details of the Sanger sequencing methodology that was used are provided in 237 
the Supplementary Information (available at www.aaojournal.org). 238 
The Rotterdam Study, a population-based study based in Rotterdam 239 
(Netherlands) was used for the replication of the findings observed in the 240 
TwinsUK. The Rotterdam study comprises of three cohorts – RSI, RSII and 241 
RSIII (combined N = 11,189). In the Rotterdam Study cohorts, imputation 242 
data was used to identify the carriers of the risk allele for rs74315329. 243 
Genotyping in these cohorts was performed using a combination of 244 
genotyping platforms - Illumina Infinium II HumanHap550 array (RS-I), the 245 
Illumina Infinium HumanHap 550-Duo array (RS-I, RS-II), and the Illumina 246 
Infinium Human 610-Quad array (RS-I, RS-III). Imputation was performed 247 
on the Michigan Imputation Server 248 
(https://imputationserver.sph.umich.edu/index.html) using the reference 249 
panel released by the Haplotype Reference Consortium (HRC) 250 
(http://www.haplotype-reference-consortium.org/). An arbitrary threshold of 251 
80% for the probability of a heterozygous genotype for rs74315329 was 252 
used to identify the risk allele carriers. Exome sequencing data that was 253 
available in a subset of the RS-I subjects
32
 was used to confirm the genotype 254 
for rs74315329 for the individuals that were identified as carriers of the risk 255 
allele for this variant using the imputation data. For all three Rotterdam 256 
cohorts, IOP from the most recent assessment, measured using Goldmann 257 
applanation tonometry, was used. The subjects in all three Rotterdam 258 
cohorts also had their optic discs and visual fields assessed in order to detect 259 
the presence of glaucomatous optic neuropathy or glaucomatous visual field 260 
loss (GVFL)
33
. In addition, any history of taking IOP-lowering medication 261 
and POAG diagnosis / surgery was also available. Further details on the 262 
Rotterdam Study are available in Hofman et al. (2016)
34
. 263 
 264 
 265 
 266 
 267 
 268 
Results 269 
In the TwinsUK, the average read depth for rs74315329 was ~7.5x and ~33x 270 
in the low-coverage and the high-coverage sequencing subsets, respectively. 271 
Seven individuals (out of a total 3,044) from the sequencing dataset were 272 
identified as heterozygous (carriers) for the risk allele (allele A) of the 273 
variant rs74315329. No individual was homozygous for the risk allele of this 274 
variant. 275 
In the 1000 Genomes–based imputation dataset for the TwinsUK, the variant 276 
rs74315329 was well imputed, with an imputation quality score (r-squared) 277 
of 0.56. The imputation dataset identified an additional two TwinsUK 278 
individuals with greater than 80% probability of a heterozygous genotype 279 
for rs74315329. In the imputation dataset, a high probability (>90%) of a 280 
heterozygous state for rs74315329 was observed in six of the seven 281 
TwinsUK individuals that were initially identified as carriers of the risk 282 
allele for this variant in the sequencing dataset (Table 1). 283 
Consequently, a total of nine unrelated individuals in the TwinsUK (out of a 284 
combined panel of 6,092 individuals) were identified as carriers of the risk 285 
allele for rs74315329, using a combination of whole genome sequencing and 286 
imputation-based data (Table 1). Seven of the nine risk allele carriers did 287 
not have data on their co-twin (in their respective datasets). In the case of the 288 
remaining two risk allele carriers that had data available on their co-twin 289 
(both were dizygotic twin pairs), the co-twin was not a carrier of the risk 290 
allele i.e. they were homozygous for the non-risk allele of rs74315329. 291 
Sanger sequencing confirmed the heterozygous genotype in eight of the nine 292 
carriers of the risk allele for rs74315329 in the TwinsUK (Supplementary 293 
Figure 1, available at www.aaojounal.org). The one risk allele carrier that 294 
failed to validate on Sanger sequencing exhibited a homozygous genotype 295 
for the non-risk allele (allele G) of rs74315329. This individual had been 296 
identified as a risk allele carrier in the sequencing dataset, and the 297 
imputation data suggested that this individual had greater than 99% 298 
probability for a heterozygous state for rs74315329 (Table 1). Since this 299 
individual belonged to the sequencing dataset, in which only one co-twin per 300 
pair was sequenced, data on the co-twin of this individual was not available. 301 
The minor allele frequency (MAF) of rs74315329 in the combined 302 
TwinsUK panel was ~0.07% (for either scenario – eight or nine risk allele 303 
carriers), which is similar to that observed in the 1000 Genomes project 304 
(0.06%). The exome sequencing databases such as EVS 305 
(http://evs.gs.washington.edu/EVS/) and ExAC 306 
(http://exac.broadinstitute.org/) report a comparatively higher MAF for 307 
rs74315329 (0.14% and 0.15%, respectively). Exome sequencing projects 308 
typically sequence at a much higher depth of coverage as compared to 309 
whole-genome sequencing projects (such as the 1000 Genomes project) – 310 
accordingly, a possible under-calling of heterozygous genotypes in the latter 311 
could explain the comparatively lower MAF (but in compliance with the 312 
1000 Genomes project) for rs74315329 observed in the TwinsUK. 313 
Table 1 provides the list of the TwinsUK samples that were identified as 314 
carriers of the risk allele for rs74315329 and their findings in the different 315 
datasets that were used. 316 
IOP information (either on initial recruitment or on follow-up) was available 317 
for eight of the nine TwinsUK individuals that were carriers of the risk allele 318 
for rs74315329. Only one of these eight mutation carriers recorded a high 319 
IOP (>21 mm Hg), either on initial measurement or on follow-up (Table 2). 320 
The mutation carrier with high IOP (Sample No. 7), on follow-up, had also 321 
developed visual field defects and had undergone trabeculectomy in both the 322 
eyes. For this individual, the IOP prior to trabeculectomy was available only 323 
for the left eye (27.3 mm Hg), while the same for the right eye was not 324 
available. Post-trabeculectomy, the most recent IOP of this individual had 325 
reduced to 12.3 mm Hg (13.3 mm Hg and 11.3 mm Hg, for the right and left 326 
eye, respectively). 327 
None of the remaining seven mutation carriers recorded a higher than 328 
normal IOP, either on initial measurement or on follow-up (a mean of five 329 
years later). In addition, none of these seven individuals had any history of 330 
taking IOP-lowering medication; and for five of these seven individuals, 331 
visual field data available from the most recent assessment at their local 332 
optician showed no GVFL. 333 
In the Rotterdam cohorts, HRC-based imputation data was used to identify 334 
individuals with a heterozygous genotype (carriers) for rs74315329. Twelve, 335 
seven and twelve individuals were identified as carriers of the risk allele for 336 
rs74315329 in the RS-I, RS-II and RS-III, respectively. The heterozygous 337 
genotype for rs74315329 was confirmed in all six carriers (out of twelve) in 338 
the RS-I that also had exome sequencing data. In the RS-I, three of the 339 
twelve carriers of the risk allele for rs74315329 who had normal IOP on 340 
assessment were on IOP-lowering medication; it is therefore assumed that 341 
these three individuals had ocular hypertension before the initiation of 342 
treatment. None of the 12 mutation carriers showed any GVFL. In the RS-II, 343 
two of the seven mutation carriers were previously diagnosed with glaucoma 344 
(with high IOP) and have had laser surgery for the same (only one of these 345 
two individuals showed GVFL on assessment). Another RS-II mutation 346 
carrier, who initially had normal IOP on IOP-lowering medication, provided 347 
history of glaucoma laser surgery on follow-up visit. In the RS-III, none of 348 
the 12 mutation carriers had high IOP, were on IOP-lowering medication, 349 
showed GVFL on assessment, or reported any history of glaucoma. Details 350 
such as the heterozygous genotype probability, IOP and age of the mutation 351 
carriers in the RS-I, RS-II and RS-III are summarised in Supplementary 352 
Table 1 (available at www.aaojounal.org). 353 
Overall, in the TwinsUK, one of the eight carriers of the risk allele for the 354 
MYOC variant rs74315329 had high IOP; while in the Rotterdam Study (RS 355 
I-III), 6 of the 31 risk allele carriers had high IOP, and three of those six 356 
individuals have been diagnosed with POAG. For rs74315329, this 357 
corresponds to a penetrance of 12.5% (95% C.I. = 0.7% - 53.3%) and 19.4% 358 
(95% C.I. = 8.1% - 38.1%) with respect to high IOP or ocular hypertension, 359 
in the TwinsUK and the Rotterdam Study, respectively. Likewise, the 360 
penetrance of rs74315329 with respect to POAG is 9.7% (95% C.I. = 2.5% - 361 
26.9%) in the Rotterdam Study, in which a complete assessment for POAG 362 
was available. An age-dependent penetrance (with respect to high IOP and 363 
POAG) of the variant rs74315329 in the TwinsUK and the Rotterdam Study 364 
is summarised in Table 3. 365 
Only one other MYOC variant (rs202176570), of the remaining 17 variants 366 
that have been catalogued in the OMIM database 367 
(http://www.omim.org/entry/601652), was non-monomorphic in the 368 
TwinsUK sequencing dataset. This variant, however, was too rare (just one 369 
heterozygous individual) to enable any meaningful assessment of its effect 370 
on IOP. 371 
 372 
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Discussion 386 
In this study, we analysed the effect of the known glaucoma-causing MYOC 387 
mutation Gln368Stop (variant rs74315329) using whole genome sequence 388 
data and imputed data based on large scale population-based sequencing 389 
panels. POAG cases with this variant often have very high IOPs, on average 390 
30 mm Hg
35
. The protein product of the MYOC gene, which has a 391 
cytoskeletal function, is widely expressed in ocular tissues, in particular the 392 
trabecular meshwork
18,36
. MYOC mutations (including the Gln368Stop 393 
mutation) lead to a buildup of abnormal protein in the trabecular meshwork, 394 
which impairs the trabecular outflow of aqueous humour, thus raising the 395 
IOP
37
. This suggests that the MYOC mutations possibly exert a toxic gain-396 
of-function effect, a finding that has been verified by MYOC-knockout 397 
studies in mice
38
. For some of the subjects in our study, comprehensive 398 
glaucoma assessment (optic disc imaging and visual field testing) was 399 
unavailable or was obtained via their local optician. Given that the disease-400 
causing MYOC mutations (including rs74315329) cause POAG by raising 401 
the IOP, the complete availability of IOP measurements in the risk allele 402 
carriers for rs74315329 allowed us to evaluate its penetrance with relation to 403 
POAG, using IOP as a proxy. In our study, seven of the eight risk allele 404 
carriers for rs74315329 in the TwinsUK, and 25 of the 31 risk allele carriers 405 
for rs74315329 in the Rotterdam Study, had IOP less than or equal to 21 mm 406 
Hg. 407 
So far, majority of the studies that have evaluated the association of the 408 
MYOC variant rs74315329 (the Gln368Stop mutation) with ocular 409 
hypertension and / or POAG have implicated a much higher penetrance 410 
compared to what was observed in our study
22,27,28,35
. For instance, 411 
Allingham et al. (1998)
27
 observed that the penetrance of the Gln368Stop 412 
mutation was 100% and 78% with respect to ocular hypertension and POAG 413 
respectively by age 70; similarly, for the same mutation, Fingert et al. 414 
(2002)
35
 reported a penetrance with respect to POAG as high as 90%. In our 415 
study, the observed penetrance of the MYOC variant rs74315329 for ocular 416 
hypertension was 12.5% and 19.4% in the TwinsUK and the Rotterdam 417 
Study, respectively. Part of the reason for the reduced penetrance of 418 
rs74315329 observed in our study is that previous studies might have 419 
overestimated its penetrance, they being either family-based studies or 420 
population-based case-control studies. Mutations can show increased 421 
penetrance in family-based studies due to more ready ascertainment of 422 
families with multiple affected individuals as well as due to the existence of 423 
additional genetic or environmental modifiers within families
39
. On the other 424 
hand, population-based case-control studies, by design, tend to oversample 425 
for cases, which can overestimate the penetrance of mutations if the 426 
population prevalence of the disease is not accounted for
40
. 427 
Accounting for the known population prevalence of POAG, we estimated 428 
the expected penetrance of rs74315329, based on the previously reported 429 
odds ratios (12.8 to 15.5) for the risk allele of rs74315329
23,26
. Given a 430 
population prevalence rate for POAG in Caucasians aged between 40 and 80 431 
years (age group of the risk allele carriers for rs74315329 observed in the 432 
TwinsUK and the Rotterdam Study) of ~2.5%
41
, the expected POAG 433 
prevalence rate among the risk allele carriers for rs74315329 (i.e. the 434 
expected penetrance of rs74315329) can be estimated to range between 435 
24.2% and 27.9% (the calculation has been approximated based on the fact 436 
that the population prevalence of POAG and the MAF of rs74315329 are 437 
both small). The observed penetrance of rs74315329 for ocular hypertension 438 
in the TwinsUK and the Rotterdam Study (12.5% and 19.4% respectively) 439 
may be even lower for POAG, since not all individuals with ocular 440 
hypertension progress to POAG
42
. In fact, POAG assessment in the 441 
Rotterdam Study has shown that thus far only three of the six mutation 442 
carriers with high IOP show any evidence of GVFL. As is evident, even 443 
after accounting for the known population prevalence of POAG, the 444 
penetrance of rs74315329 for ocular hypertension, and by extension for 445 
POAG, observed in our study, is lower than what would be expected based 446 
on the odds ratio estimates reported by previous studies. 447 
Since the penetrance of the variant rs74315329 in relation to POAG is 448 
known to increase with age
27,28
, a finding that was also corroborated by our 449 
study (Table 3),  the age of our cohorts in comparison to the previous 450 
studies is an important consideration. Alward et al. (1998)
22
, one of the 451 
studies that we used for the estimation of the expected penetrance of 452 
rs74315329 (as described above), reported that the average age of POAG 453 
diagnosis among the Gln368Stop mutation carriers in their study was 59 454 
years. In our study, the mean age of the 32 mutation carriers that did not 455 
have raised IOP or a diagnosis of POAG was 65.2 years. In the case of our 456 
youngest cohort (RS-III), though all the twelve mutation carriers (without 457 
raised IOP or a diagnosis of POAG), barring one, were older than 50 years, 458 
only three of them were older than 59 years. For the remaining three cohorts 459 
(TwinsUK, RS-I and RS-II), 19 of the 20 mutation carriers without raised 460 
IOP or a diagnosis of POAG were older than 59 years. Thus, barring the RS-461 
III to an extent, we do not expect the age of our cohorts to significantly 462 
impact the estimation of the penetrance of the MYOC variant. 463 
To date, in the studies that evaluated the penetrance of mutations, the 464 
number of control subjects that were analysed was limited in number. The 465 
recent availability of large-scale population-based sequencing panels has 466 
made it possible to ascertain the penetrance of a number of known disease-467 
causing mutations using sufficiently powered population-based studies. We 468 
believe that our estimation of the penetrance of the Gln368Stop MYOC 469 
mutation i.e. rs74315329 using a population-based panel of over 17,000 470 
subjects might represent a more “realistic” measure of its penetrance 471 
compared to its previous estimates. 472 
This observation of a lower than expected penetrance of the MYOC variant 473 
rs74315329 is in accordance with recent findings for mutations that have 474 
previously been implicated in diseases
31,43,44
. Narasimhan et al. (2016)
44
 475 
sequenced the exomes of ~3,000 Pakistanis with high levels of 476 
consanguinity and observed that there were as many as 29 instances of rare 477 
homozygous loss-of-function mutations in genes catalogued in the OMIM 478 
database in individuals that showed no manifestations consistent with the 479 
expected OMIM phenotype. 480 
The implication of the reduced penetrance of the Gln368Stop MYOC 481 
mutation (which results in premature termination of the myocilin protein) is 482 
that higher numbers of healthy individuals in the population are expected to 483 
be carriers of this mutation than estimated previously. Hence, the finding of 484 
this mutation in an individual would require cautious interpretation. The 485 
reduced penetrance also implies that the genotype-phenotype correlation 486 
between this mutation and POAG is likely to be much weaker than estimated 487 
previously, thus potentially reducing the utility of knowing the genotype at 488 
rs74315329 as a predictive tool in identifying those at a high-risk of 489 
developing POAG. Nonetheless, given the difficulties and poor efficacy of 490 
screening for glaucoma with current paradigms
45
, using genetic variants that 491 
offer even modest predictive value might still be useful to target subjects for 492 
screening. 493 
A limitation of the TwinsUK cohort is that it is a volunteer-based cohort 494 
with a potential “healthy volunteer” bias. If such a bias were true, then twins 495 
suffering from sight-impairing severe glaucoma might be less likely to 496 
volunteer. However, the prevalence of common diseases and lifestyle 497 
characteristics in the TwinsUK is comparable to that of age-matched 498 
population-based studies
46
. Moreover, the estimated prevalence of the 499 
variant rs74315329 in the TwinsUK is similar to the expected population 500 
prevalence. Another potential limitation of our study is that in the Rotterdam 501 
cohorts the variant rs74315329 was imputed, and it was possible to confirm 502 
the imputation calls in only a subset of them that were also sequenced. But 503 
given that Sanger sequencing validated the imputation calls for this variant 504 
in the TwinsUK, and that previous studies have confirmed the validity of 505 
imputation for this variant
26
, this is unlikely to have a significant impact on 506 
our results. 507 
In conclusion, we reported the findings of the largest study to date 508 
evaluating the penetrance of the most common genetic mutation causing 509 
POAG. Given the rarity of this mutation and its much lower penetrance 510 
(than known previously) for ocular hypertension (and hence, POAG), our 511 
study suggests that screening for this mutation would not be useful on its 512 
own. But known carriers of this mutation would require careful monitoring, 513 
although they might be reassured that it is not always disease-causing.  514 
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